Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER(?)) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and intolerability. New agents with improved toxicity...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Autores principales: Arun, Banu K., Gong, Yun, Liu, Diane, Litton, Jennifer K., Gutierrez-Barrera, Angelica M., Lee, J. Jack, Vornik, Lana, Ibrahim, Nuhad K., Cornelison, Terri, Hortobagyi, Gabriel N., Heckman-Stoddard, Brandy M., Koenig, Kimberly B., Alvarez, Ricardo R., Murray, James L., Valero, Vicente, Lippman, Scott M., Brown, Powel, Sneige, Nour
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989315/
https://ncbi.nlm.nih.gov/pubmed/27287781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3849-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares